French researchers from the Institute of Myology, Genethon and Atamyo, in collaboration with Dutch researchers, have studied several quantitative MRI parameters in order to identify sensitive and non-invasive biomarkers for assessing the progression of LGMD-R9 and evaluating the efficacy of new therapies.
Carried out in 18 persons with LGMD-R9 and 13 controls, this study shows that muscle fat fraction (MF), T2 water, T1 water and intramuscular pH are effective biomarkers for LGMD-R9. The correlation of some of the parameters tested suggests their potential in predicting disease progression.
